Figure 7.

Ad-BD2-E1A-induced immune responses are abrogated in TLR4-deficient mice. JC tumor cells were subcutaneously inoculated into right flank of TLR4-deficient and wild type (WT) Balb/c mice (N = 6 in each group). Mice were intratumorally treated with 10¹⁰ ifu of Ad-BD2-E1A three times as described in Figure 3. (a) Tumor growth was monitored until tumors reached about 10 mm in diameter in TLR4-deficient group (15–16 days after first intratumoral injection). Error bars represent standard error of the mean. (b) IFN-γ ELIspot assay was used to determine the number of JC-specific T cells induced in TLR4-deficient and WT Balb/c mice by Ad-BD2-E1A vaccine. IFN, interferon; TLR, toll-like receptor.